Sofwave Receives FDA Clearance for Pure Impact™ in Strengthening and Firming of Arms in the U.S.
August 12, 2024 08:00 ET
|
SofWave Medical, Ltd.
Latest Pure Impact™ indication expansion includes strengthening and improvement in muscle tone and firmness of the armsRepresents next major step toward Pure Impact™ covering multiple body areas and...
Sofwave to Participate in 9th Annual Needham Virtual MedTech & Diagnostics Conference
August 09, 2024 08:00 ET
|
SofWave Medical, Ltd.
SAN CLEMENTE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced...
Sofwave Medical Reports Second Quarter and First Half 2024 Financial Results and Business Highlights
August 06, 2024 08:30 ET
|
SofWave Medical, Ltd.
Second quarter revenue of $14.6M, +18% year-over-year growth; IFRS gross margin of 76.1%Second quarter pulse recurring revenue of $6.0M, +83% year-over-year growthFirst half revenue of $27.8M, +22%...
Sofwave Medical Receives Marketing Clearance in Canada for Pure Impact™ Strength and Muscle Toning Device
June 11, 2024 08:33 ET
|
SofWave Medical, Ltd.
– Approval by Health Canada regulatory authority immediately clears the way for Pure Impact™ with PlyoPulse™ device launch and commercialization in Canada – Canada Represents Another Substantial...
Sofwave Medical Reports First Quarter 2024 Financial Results and Business Highlights
May 09, 2024 08:30 ET
|
SofWave Medical, Ltd.
First quarter revenue of $13.2M, +27% year-over-year growth; IFRS gross margin of 75.2%First quarter pulse recurring revenue of $4.7M, +118% year-over-year growth IFRS and non-IFRS...
Sofwave Medical to Participate in the Needham 23rd Annual Healthcare Conference
March 28, 2024 08:00 ET
|
SofWave Medical, Ltd.
SAN CLEMENTE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide,...
Sofwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 06, 2024 08:30 ET
|
SofWave Medical, Ltd.
– Full fiscal 2023 revenue of $50.3M, +41% year-over-year growth; gross margin of 74.5% – Full fiscal 2023 pulse recurring revenue of $13.0M, +81% year-over-year growth – Fourth quarter revenue...
Sofwave Medical to Present Pure Impact™ Strength and Muscle Toning Module’s First U.S. Industry Reveal at the 2024 American Academy of Dermatology (AAD) Annual Meeting
March 04, 2024 08:30 ET
|
SofWave Medical, Ltd.
SAN CLEMENTE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, is excited to...
Sofwave Medical to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
February 28, 2024 08:00 ET
|
SofWave Medical, Ltd.
SAN CLEMENTE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced...
Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer
February 12, 2024 08:30 ET
|
SofWave Medical, Ltd.
SAN CLEMENTE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners...